The gray area of RQ-PCR-based measurable residual disease: subdividing the "positive, below quantitative range" category

Detection of measurable residual disease (MRD) in hematological malignancies is crucial for prognostication and treatment decisions. Real-time quantitative PCR (RQ-PCR), which targets immunoglobulin (IG) and T-cell receptor (TR) rearrangements, is deemed the gold-standard method for MRD detection in national and international clinical trials. However, this approach does have some limitations, primarily related to standard curve performance and non-specific background amplification.

Preview

Additional data

Published in:
Leukemia : the journal of normal and malignant hemopoiese ; official journal of the Leukemia Research Fund U.K.
Publisher:
Springer Science and Business Media LLC
Williams & Wilkins
Macmillan
Nature Publ. Group
Publishing place:
London
Baltimore, Md.
Basingstoke
Basingstoke
Vol.:
38
No.:
7
ISSN:
0887-6924
ISSN:
1476-5551
Pages:
1617 - 1620
Date Issued:
2024
URN:
urn:nbn:de:gbv:8:3-2026-01156-7
DOI:
10.1038/s41375-024-02265-z
Other identifier (pubmed):
38760480
Language:
English
Type of Resource:
Text
Publisher:
Springer Science and Business Media LLC
Keywords:
Humans; Neoplasm, Residual; Real-Time Polymerase Chain Reaction
Classification:
Published version
DDC subject of DNB:
610 Medical sciences, health
Hosting institution:
Faculties, Faculty of Medicine

Rights

Use and reproduction:


CC BY 4.0

Please note that individual components of the publication may be subject to other licensing or copyright conditions.

For further information please read the FAQ about Rights.

Cite

Citation style:
Could not load citation form.